Vaccine Therapy for Blood Cancers
Trial Summary
What is the purpose of this trial?
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.
Research Team
Ryotaro Nakamura, MD
Principal Investigator
City of Hope Medical Center
Eligibility Criteria
This trial is for patients with blood cancers like lymphoma, leukemia, and myelodysplastic syndrome who are undergoing stem cell transplants. They must understand the study, agree to follow-up procedures for a year post-transplant, be HLA A*0201 positive, CMV seropositive, not pregnant or breastfeeding, willing to use contraception and have no recent experimental anti-CMV treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CMVpp65-A*0201 peptide vaccine or placebo subcutaneously on days 28 and 56 after HCT
Follow-up
Participants are monitored for safety and effectiveness after treatment, including CMV reactivation and immune response
Treatment Details
Interventions
- CMVpp65-A*0201 peptide vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator